Key result
Differentiating cardiac sarcoidosis from mimics requires multimodal histological, molecular, and imaging evaluation.
Accurate diagnosis of cardiac sarcoidosis requires thorough evaluation to rule out treatable granulomatous mimics, guiding appropriate immunosuppressive or antimicrobial therapy.
May support multimodal differentiation from granulomatous mimics before immunosuppression; leaves open standardized diagnostic criteria.
In this narrative review of cardiac sarcoidosis, based on a literature search using the terms "cardiac sarcoidosis", "tuberculous myocarditis", "Whipple's disease and myocarditis", and"idiopathic giant cell myocarditis", I have defined cardiac sarcoidosis as a disorder which can be diagnosed either by documentation of the presence of sarcoid-related granulomas in myocardial tissue or by documentation of the association of the presence of sarcoid-related granulomas in extracardiac tissue and symptoms such as complete heart block, ventricular tachyarrhythmia, sudden death or dilated cardiomyopathy which are typical of cardiac sarcoidosis. The differential diagnosis of cardiac sarcoidosis includes granulomatous myocarditis attributable to underlying causes such as such as tuberculosis, Whipple's disease, and idiopathic giant cell myocarditis. Diagnostic pathways for cardiac sarcoidosis include biopsy of cardiac and extracardiac tissue, nuclear magnetic resonance imaging, positron emission tomography, and a diagnostic trial of empiric therapy. Problem areas include differentiation between noncaseating granulomatosis attributable to sarcoidosis versus noncaseating granulomatosis attributable to tuberculosis and whether or not the workup of suspected cardiac sarcoidosis should always include evaluation of biopsy tissue by molecular methods for M tuberculosis DNA as well as by mycobacterium tuberculosis culture. The diagnostic significance of necrotising granulomatosis is also unclear. Evaluation of patients on long term immunotherapy should also take due account of the risk of tuberculosis attributable to the use of tumor necrosis factor-alpha antagonists.
No takes yet. Share an insight, caveat, or question.
Oscar M.P. Jolobe (2023) conducted a review in Cardiac sarcoidosis and its mimics (tuberculous myocarditis, Whipple's disease, idiopathic giant cell myocarditis). Diagnostic and therapeutic pathways for cardiac sarcoidosis was evaluated. Diagnostic evaluation for cardiac sarcoidosis requires careful differentiation from mimics such as tuberculosis, Whipple's disease, and idiopathic giant cell myocarditis using histological, molecular, and imaging techniques.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: